Metaraminol Laboratoire Aguettant (Metaraminol)

Metaraminol acts as a direct agonist at alpha‑1 adrenergic receptors on vascular smooth muscle. Activation of these receptors causes vasoconstriction, which increases systemic vascular resistance and arterial pressure. The rise in vascular tone supports cardiac output and helps reverse low‑blood‑pressure states without relying on indirect catecholamine release.

The dosage of Metaraminol is individualized by the prescribing clinician based on the patient’s condition, severity of hypotension, and response to therapy. Healthcare professionals determine the appropriate infusion rate or bolus amount and adjust it according to continuous hemodynamic monitoring.

Safety data for Metaraminol in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Metaraminol is a direct alpha‑1 agonist, offering rapid and predictable vasoconstriction. Compared with agents like norepinephrine, which have mixed alpha and beta activity, Metaraminol provides a more focused increase in vascular tone with less tachycardia. Choice of vasopressor depends on the clinical scenario, patient comorbidities, and physician preference.

Metaraminol should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and sterility.

Metaraminol is administered intravenously, either as a slow bolus or continuous infusion, depending on the clinical need. Administration is performed by qualified healthcare personnel under continuous monitoring of blood pressure, heart rate, and other vital signs.

Serious risks include severe hypertension, arrhythmias, myocardial ischemia, tissue necrosis from extravasation, pulmonary edema, and rare anaphylactic reactions. Prompt recognition and management of these events are essential, and patients should be monitored closely during and after infusion.

Metaraminol is contraindicated in patients with known hypersensitivity to the drug, uncontrolled hypertension, or severe peripheral vascular disease where further vasoconstriction could be harmful. Caution is also advised in individuals with significant cardiac disease, recent myocardial infarction, or those taking monoamine oxidase inhibitors.